{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T23:41:19Z","timestamp":1781134879557,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.remnie.2022.09.005","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T14:21:22Z","timestamp":1663770082000},"page":"3-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The efficacy of 18F-FDG PET\/CT in monitoring disease progression in malignant pleural mesothelioma"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9267-8326","authenticated-orcid":false,"given":"Yasemin","family":"S\u00f6yler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zlem","family":"\u00d6zmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u0131nar Ak\u0131n","family":"Kabalak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Ert\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feza","family":"U\u011furman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00dclk\u00fc","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.remnie.2022.09.005_bib0005","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00953-2019","article-title":"ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma","volume":"55","author":"Scherpereel","year":"2020","journal-title":"Eur Respir J"},{"issue":"14","key":"10.1016\/j.remnie.2022.09.005_bib0010","doi-asserted-by":"crossref","first-page":"896","DOI":"10.21037\/atm.2020.03.58","article-title":"Malignant pleural mesothelioma: between pragmatism and hope","volume":"8","author":"Migliore","year":"2020","journal-title":"Ann Transl Med"},{"issue":"2","key":"10.1016\/j.remnie.2022.09.005_bib0015","first-page":"134","article-title":"Diagnostic imaging and workup of malignant pleural mesothelioma","volume":"88","author":"Cardinale","year":"2017","journal-title":"Acta Biomed"},{"issue":"1","key":"10.1016\/j.remnie.2022.09.005_bib0020","doi-asserted-by":"crossref","DOI":"10.1186\/s13550-020-00669-3","article-title":"FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients","volume":"10","author":"Pavic","year":"2020","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.remnie.2022.09.005_bib0025","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.15796.1","article-title":"Multimodality treatment of malignant pleural mesothelioma","volume":"7","author":"Berzenji","year":"2018","journal-title":"F1000Res"},{"issue":"4","key":"10.1016\/j.remnie.2022.09.005_bib0030","first-page":"177","article-title":"Diagnosis and treatment of malignant pleural mesothelioma","volume":"51","author":"Panadero","year":"2015","journal-title":"Arch Bronconeumol"},{"issue":"2","key":"10.1016\/j.remnie.2022.09.005_bib0035","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2214\/AJR.13.10572","article-title":"FDG PET\/CT in the management of primary pleural tumors and pleural metastases","volume":"201","author":"Kruse","year":"2013","journal-title":"Am J Roentgenol"},{"issue":"5","key":"10.1016\/j.remnie.2022.09.005_bib0040","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.jtcvs.2014.10.128","article-title":"Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma","volume":"149","author":"Baldini","year":"2015","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.remnie.2022.09.005_bib0045","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thoraxjnl-2017-211321","article-title":"British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma","volume":"73","author":"Woolhouse","year":"2018","journal-title":"Thorax"},{"issue":"7","key":"10.1016\/j.remnie.2022.09.005_bib0050","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jtho.2018.04.034","article-title":"Revised modified response evaluation criteria in solid tumors for assessment of response in malignant pleural mesothelioma (Version 1.1)","volume":"13","author":"Armato","year":"2018","journal-title":"J Thorac Oncol."},{"issue":"2","key":"10.1016\/j.remnie.2022.09.005_bib0055","doi-asserted-by":"crossref","first-page":"53","DOI":"10.5306\/wjco.v11.i2.53","article-title":"Objective response rate assessment in oncology: current situation and future expectations","volume":"11","author":"Aykan","year":"2020","journal-title":"World J Clin Oncol"},{"issue":"3","key":"10.1016\/j.remnie.2022.09.005_bib0060","first-page":"191","article-title":"18F-FDG PET\/CT in therapy response and in predicting responders or non-responders in malignant pleural mesothelioma patients, by using semi-quantitative mRECIST and EORTC criteria","volume":"21","author":"Asabella","year":"2018","journal-title":"Hell J Nucl Med"},{"key":"10.1016\/j.remnie.2022.09.005_bib0065","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0169-5002(03)00292-7","article-title":"Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma","volume":"43","author":"van Klaveren","year":"2004","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.remnie.2022.09.005_bib0070","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.jtho.2016.09.124","article-title":"The IASLC mesothelioma staging project: proposals for the M descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for mesothelioma","volume":"11","author":"Rusch","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.remnie.2022.09.005_bib0075","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejrad.2016.11.009","article-title":"Metabolic response assessment with 18F-FDG-PET\/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma","volume":"86","author":"Kanemura","year":"2017","journal-title":"Eur J Radiol"},{"issue":"2","key":"10.1016\/j.remnie.2022.09.005_bib0080","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Bryne","year":"2004","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.remnie.2022.09.005_bib0085","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","article-title":"Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Ca","volume":"35","author":"Young","year":"1999","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.remnie.2022.09.005_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41747-020-00190-1","article-title":"PET\/CT imaging for tumour response assessment to immunotherapy: current status and future directions","volume":"4","author":"Unterrainer","year":"2020","journal-title":"Eur Radiol Exp"},{"issue":"6","key":"10.1016\/j.remnie.2022.09.005_bib0095","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.clinimag.2013.06.009","article-title":"18F-FDG PET\/CT in suspected recurrences of epithelial malignant pleural mesothelioma in asbestos-fibers-exposed patients (comparison to standard diagnostic follow-up)","volume":"37","author":"Asabella","year":"2013","journal-title":"Clin Imaging"},{"issue":"2","key":"10.1016\/j.remnie.2022.09.005_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0229299","article-title":"Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET\/CT scan in patients with malignant pleural mesothelioma","volume":"15","author":"Lim","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.remnie.2022.09.005_bib0105","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00259-014-2960-y","article-title":"Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma","volume":"42","author":"Lopci","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.remnie.2022.09.005_bib0110","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.ejrad.2010.11.006","article-title":"Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET\/CT","volume":"81","author":"Schaefer","year":"2012","journal-title":"Eur J Radiol"},{"issue":"63","key":"10.1016\/j.remnie.2022.09.005_bib0115","doi-asserted-by":"crossref","first-page":"6816","DOI":"10.18632\/oncotarget.27324","article-title":"Clinical utility of FDG-PET\/CT for post-surgery surveillance of malignant pleural mesothelioma \u2013 comparison with contrast-enhanced CT","volume":"10","author":"Kitajima","year":"2019","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.remnie.2022.09.005_bib0120","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13051098","article-title":"Response to immune checkpoint inhibitor therapy in patients with unresectable recurrent malignant pleural mesothelioma shown by FDG-PET and CT","volume":"13","author":"Kitajima","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1086","key":"10.1016\/j.remnie.2022.09.005_bib0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1259\/bjr.20170814","article-title":"18F-FDG PET\/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: Experience of a tertiary referral center","volume":"91","author":"Elliott","year":"2018","journal-title":"Br J Radiol"},{"issue":"3","key":"10.1016\/j.remnie.2022.09.005_bib0130","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.cllc.2020.06.002","article-title":"Delayed-phase enhancement for evaluation of malignant pleural mesothelioma on computed tomography: a prospective cohort study","volume":"22","author":"Patel","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.remnie.2022.09.005_bib0135","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s13014-015-0575-5","article-title":"Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy","volume":"10","author":"Thieke","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.remnie.2022.09.005_bib0140","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1200\/JCO.2006.06.8999","article-title":"Early response evaluation in malignant pleural mesothelioma by positron emission tomography with (18F) fluorodeoxyglucose","volume":"24","author":"Ceresoli","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808922000945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808922000945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T08:45:10Z","timestamp":1762418710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2253808922000945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2253808922000945"],"URL":"https:\/\/doi.org\/10.1016\/j.remnie.2022.09.005","relation":{},"ISSN":["2253-8089"],"issn-type":[{"value":"2253-8089","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy of 18F-FDG PET\/CT in monitoring disease progression in malignant pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.remnie.2022.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.remn.2022.06.005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Sociedad Espa\u00f1ola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}